FDA Clearance Tracker · P850048-S022
ACCESS HYBRITECH PSA REAGENTS ON THE ACCESS IMMUNOASSAY SYSTEMS
Last checked: Nov 20, 2026Latest source record: Sep 18, 2007 (this decision)Source: openFDAMethods & limitations
Decided
Sep 18, 2007
Approved
Time to decision
125 days
Received May 16, 2007. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P850048-S022
- Device name
- ACCESS HYBRITECH PSA REAGENTS ON THE ACCESS IMMUNOASSAY SYSTEMS
- Applicant
- Beckman Coulter, Inc.
- Applicant location
- Brea, CA
- Received
- May 16, 2007
- Decided
- Sep 18, 2007
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P850048
Device type
- Device type
- Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer (MTF)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE USE OF THE ACCESS (HYBRITECH) PSA REAGENTS ON THE UNICEL DXI 600 ACCESS IMMUNOASSAY SYSTEM.
Source documents
Other decisions for Beckman Coulter, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Access BNP II510(k)
K262597 · Decided Oct 20, 2026 · 85 days after receipt
Device type: Test, Natriuretic Peptide (NBC) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.